Strangeloop launches Network Accelerator, the first end-to-end optimization solution for global network providers
Today we are extremely excited to announce the launch of our latest web performance optimization product: the Strangeloop Network Accelerator.
Our Network Accelerator is the world’s first product to offer global network providers end-to-end acceleration capabilities. The product is designed to help networks manage burgeoning global internet traffic, facilitate the ever-increasing complexity of pages, and accommodate the increasing share of wireless mobile devices hampered by network and bandwidth limitations.
Network Accelerator is designed to help telecommunications providers become next-generation content delivery networks by leveraging their existing content delivery network (CDN) infrastructure to provide end-to-end acceleration. The product layers three acceleration elements on top of the existing CDN:
- Near-Client Edge Acceleration powered by our proprietary LightSpeed edge platform,
- Middle-Mile Acceleration powered by our innovative dynamic site acceleration (DSA) technology, and
- Near-Server Edge Acceleration powered by our award-winning front-end optimization (FEO) platform.
The result is a product that delivers content at least 30% faster than competing solutions – allowing network operators to offer their customers the fastest, most cost-effective CDN on the market.
What makes Network Accelerator different?
We give network providers end-to-end control of content delivery, allowing them to enhance value to customers by delivering superior performance. Networks have traditionally abdicated responsibility for content delivery to third-party services – often at prohibitive costs to end users. Chris Wilson, SVP Product Strategy & Management at Pacnet, notes that “Adding network acceleration technology can make our already-fast network even faster, while still allowing us to retain complete control.”
Visit Strangeloop’s official Network Accelerator page for feature descriptions, product specifications, and the latest testing results.